title: Evidence-based urology in practice: when to believe a subgroup analysis?
authors.affiliation: Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
authors.forename: Shian-Shiang
authors.initials: SS
authors.lastname: Wang
authors.forename: Yen-Chuan
authors.initials: YC
authors.lastname: Ou
authors.forename: Chen-Li
authors.initials: CL
authors.lastname: Cheng
authors.forename: Philipp
authors.initials: P
authors.lastname: Dahm
mesh_terms: D000367:Age Factors; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib